153888-47-2

Basic information

• Product Name: Methyl 5-bromo-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate
• Synonyms: Methyl 5-bromo-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate
• CAS NO: 153888-47-2
• Molecular Formula: C₈H₈BrNO₃
• Molecular Weight: 246.05802
• EINECS: -0
• Mol File: 153888-47-2.mol

Chemical Properties

• Boiling Point: 325.4±42.0 °C(Predicted)
• Appearance: /
• Density: 1.656±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: -4.45±0.62(Predicted)
• CAS DataBase Reference: Methyl 5-bromo-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 5-bromo-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate(153888-47-2)
• EPA Substance Registry System: Methyl 5-bromo-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate(153888-47-2)

Safety Data

• Hazardous Substances Data: 153888-47-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 5-bromo-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate is used as a starting material for the synthesis of Functionalized Tricyclic Pyrrolo-Pyridones. These tricyclic compounds have shown promising biological activities, including potential applications in the treatment of various diseases and disorders. The synthesis of these compounds often involves the use of Methyl 5-bromo-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate as a key building block, highlighting its importance in the development of new pharmaceutical agents.

Upstream product

• 6375-89-9 methyl 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate 
• 381247-99-0 methyl 5-bromo-6-oxo-1,6-dihydropyridine-3-carboxylate 
• 74-88-4 methyl iodide 
• 41668-13-7 5-bromo-6-oxo-1,6-dihydropyridine-3-carboxylic acid 
• 6018-41-3 methyl coumalate 

Downstream Products

• 939411-78-6 methyl 1-methyl-6-oxo-5-(pyridin-2-yl)-1,6-dihydropyridine-3-carboxylate 
• 934189-20-5 methyl 5-(2,6-difluorophenyl)-1-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 

Relevant articles and documents

Expeditious Access to Functionalized Tricyclic Pyrrolo-Pyridones via Tandem or Sequential C-N/C-C Bond Formations

The facile synthesis of both saturated and unsaturated tricyclic pyrrolo-pyridones starting from a single readily available, common monocyclic reagent has been developed. An intermolecular annulation via a tandem Buchwald-Hartwig/Heck reaction led to the synthesis of β-carbolinones. The analogous semisaturated tricyclic pyrrolo-pyridones were prepared in good to excellent yields by sequential Buchwald-Hartwig and Fischer indole reactions. The methods feature mild reaction conditions and good functional group tolerance.

Discovery of a Potent and Selective ATAD2 Bromodomain Inhibitor with Antiproliferative Activity in Breast Cancer Models

ATAD2 is an epigenetic bromodomain-containing target which is overexpressed in many cancers and has been suggested as a potential oncology target. While several small molecule inhibitors have been described in the literature, their cellular activity has proved to be underwhelming. In this work, we describe the identification of a novel series of ATAD2 inhibitors by high throughput screening, confirmation of the bromodomain region as the site of action, and the optimization campaign undertaken to improve the potency, selectivity, and permeability of the initial hit. The result is compound 5 (AZ13824374), a highly potent and selective ATAD2 inhibitor which shows cellular target engagement and antiproliferative activity in a range of breast cancer models.

PCSK9 INHIBITORS AND METHODS OF USE THEREOF

The invention relates to a novel inhibitor pharmacophore of PCSK9 and heteroaryl compounds that bind the PCSK9 protein.

PCSK9 INHIBITORS AND METHODS OF USE THEREOF

The invention relates to novel heteroaryl compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cardiovascular diseases, and methods treating sepsis or septic shock, using the novel heterocyclic compounds disclosed herein.

PYRIDINYL BASED APOPTOSIS SIGNAL-REGULATION KINASE INHIBITORS

Apoptosis signal-regulating kinase 1 (ASK1) activation and signaling have been reported to play an important role in a broad range of diseases including neurodegenerative, cardiovascular, inflammatory, autoimmunity and metabolic disorders. Disclosed herein is the synthesis of pyridinyl derived therapeutic agents that function as inhibitors of ASK 1 as well as their pharmaceutical compositions and methods of use.

NOVEL ANTIFUNGAL OXODIHYDROPYRIDINECARBOHYDRAZIDE DERIVATIVE

The present invention relates to novel oxodihydropyridinecarbohydrazide derivatives with excellent antifungal activities, an antifungal composition containing the same, and its use for the prevention and treatment of fungal infectious diseases. The oxodihydropyridinecarbohydrazide derivatives of the present invention have excellent antifungal and fungicidal activities, and thus will be useful for the prevention and treatment of various fungal infections by Candida spp., Aspergillus spp., Cryptococcus neoformans and Trichophyton spp., etc. Additionally, the oxodihydropyridinecarbohydrazide derivatives of the present invention, unlike other fungicidal preparations, can be orally administered.

NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF

It is intended to provide a compound represented by the general formula (I): (I) (wherein all the symbols are as defined in the description) which has a p38 MAP kinase inhibitory activity, a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. The compound of the invention is useful for preventing or treating a disease in which the abnormal production of a cytokine such as an inflammatory cytokine or a chemokine or overreaction to them is considered to be involved in the cause and aggravation of pathological conditions, in other words, an inflammatory disease, a respiratory disease, a cardiovascular disease, a central nervous system disease or the like, which is a cytokine-mediated disease.

BETA-SECRETASE MODULATORS AND METHODS OF USE

The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, B, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.